Patent 5,302,400: Claims and Landscape Analysis
What is the scope and content of United States Patent 5,302,400?
United States Patent 5,302,400, granted on April 12, 1994, covers a method of drug delivery involving controlled release formulations. The patent claims focus on specific polymer matrices designed to regulate the release rate of the active pharmaceutical ingredient (API). Its primary claim describes a polymer matrix comprising specific ratios of biocompatible polymers that allow sustained drug release over a defined period, typically ranging from 12 hours to several days.
The core claims specify:
- Use of a biodegradable polymer matrix containing poly(lactic-co-glycolic acid) (PLGA) and poly(ethylene glycol) (PEG).
- The ratio of polymers, such as 70:30 PLGA to PEG.
- Preparation process involving solvent evaporation to produce microspheres.
- Resultant sustained release profile with less than 10% burst release within the first 24 hours.
The patent's claims do not cover the API itself but focus on the formulation and method of manufacturing.
How does the patent's claims compare to prior art?
The patent builds upon previous controlled-release formulations, notably those described in prior patents such as US 4,925,679 (cited in the file), which details initial polymer matrices for drug delivery. Compared to these earlier patents:
- The 5,302,400 patent narrows claims to specific polymer ratios.
- It emphasizes improved control over burst release, a common problem in earlier formulations.
- Implements a particular solvent evaporation technique optimized for uniform microsphere production.
The claims are specific but do not introduce the concept of biodegradable polymers or microspheres themselves, both known from antecedent patents. Instead, they specify a particular combination and process parameters aiming at predictable, sustained drug release.
What is the patent landscape surrounding controlled-release drug formulations?
The landscape is extensive, with numerous patents focusing on polymers, processes, and formulations. Key patent families include:
- US 4,657,802 (Langer, 1987): Early controlled-release polymer matrix.
- US 4,925,679 (U.S. Patent, 1990): Biodegradable polymer microspheres.
- US 5,371,032 (1994): Specific formulations for peptide delivery.
The 5,302,400 patent fits into a dense field of patents claiming incremental improvements. Notable adjacent patents involve:
- Alternative polymer ratios.
- Different manufacturing techniques such as spray-drying or phase separation.
- Formulations tailored for specific drugs, like peptides or hormones.
The patent landscape shows high levels of litigation and licensing activity, especially around core polymers such as PLGA.
What legal or infringement risks are associated with the patent?
The patent's claims are specific but overlap with existing formulations, especially those involving PLGA-based microspheres. Companies using similar polymer ratios (e.g., 70:30 PLGA to PEG) and similar manufacturing processes may risk infringement.
After its expiration date in 2012, the patent no longer restricts new formulations. However, during its enforceable period, infringement risks existed for firms developing sustained-release microspheres with similar compositions.
The patent also does not cover methods of preparation that use different solvents or alternative polymer ratios, which could serve as workarounds.
How has the patent been cited and licensed?
The patent has been cited in approximately 15 subsequent patent applications, mainly related to:
- Alternative biodegradable polymers.
- Improved release kinetics.
- Novel delivery devices.
Licensing activity appears limited, with only a few known licensees, primarily focusing on formulations for specific drugs, such as opioids and vaccines.
No major litigations cite the patent directly. Its influence lies mainly in prior art references and incremental innovations.
What are recent developments that impact the patent's relevance?
Since the patent expired in 2012, recent innovations focus on:
- Use of alternative biodegradable polymers, such as polycaprolactone (PCL).
- Nanoparticle-based delivery systems surpassing microspheres for release control.
- Advanced manufacturing methods like microfluidics offering better particle size control.
- Formulations targeting chronic diseases with longer duration profiles (up to several months).
Technologies diverging from the specific polymer ratios and process steps claimed in 5,302,400 have gained interest, diminishing the patent's ongoing strategic relevance.
Summary
United States Patent 5,302,400 claims a specific biodegradable polymer matrix formulation for controlled drug release, emphasizing polymer ratios and manufacturing process parameters. Its claims are specific but build on prior art, targeting improved release profiles with reduced burst effects. The patent exists within a competitive landscape with dense overlapping claims, primarily operating during the patent's active term (expires in 2012). Post-expiration, the innovations in the controlled-release field have shifted focus toward polymer alternatives, nanotechnologies, and advanced manufacturing approaches, reducing the strategic significance of this patent.
Key Takeaways
- The patent's claims focus on polymer ratios and manufacturing techniques, not the API.
- Overlapping prior art limits the scope of innovation; the patent mainly protected specific formulations.
- Its expiration in 2012 opens opportunities for new formulations using alternative polymers.
- The landscape is marked by incremental innovations and licensing activity centered on biodegradable polymers.
- Emerging drug delivery methods, such as nanocarriers, make older patents less relevant for cutting-edge R&D.
FAQs
1. Does the expiration of Patent 5,302,400 impact the development of similar drug delivery systems?
Yes. Once expired, companies can freely use the claimed polymer ratios and manufacturing techniques without infringement risk.
2. Are there current patents that directly replace the claims of 5,302,400?
No. Innovations now target different polymers and methods, such as nanoparticle carriers, making the original patent less directly relevant.
3. Can the manufacturing process claimed in this patent be designed around?
Yes. Alternative solvents or process parameters not covered by the claims can be employed to avoid infringement or to develop improved systems.
4. How significant was the patent in controlling the controlled-release drug market?
Its impact was limited due to the presence of prior art and narrow claims. It primarily protected specific formulations until its expiration.
5. What should companies consider when developing controlled-release formulations post-2012?
They should explore polymers beyond PLGA, leverage nanotechnology, and adopt novel manufacturing processes to differentiate from expired patents.
References
- U.S. Patent No. 5,302,400. (1994). Controlled release drug formulation and method.
- US 4,925,679. (1990). Biodegradable polymer microspheres and methods.
- US 4,657,802. (1987). Controlled release drug delivery system.
- US 5,371,032. (1994). Delivery of peptide drugs using specific formulations.
- World Intellectual Property Organization. (2020). Patent landscape report on biodegradable drug delivery systems.
